$ABOS News

Acumen's Late-2026 Sabirnetug Readout Is A Viable Bet

Acumen Pharmaceuticals, Inc. (ABOS) Presents at Bank of America Global Healthcare Conference 2026 Transcript

Acumen Pharmaceuticals (NASDAQ:ABOS) Q1 2026 Loss Narrows as Phase 2 Alzheimer's Trial Readout Looms

Acumen Pharmaceuticals, Inc. (ABOS) Q1 2026 Earnings Call Transcript

Acumen Pharmaceuticals Reports Q1 2026 Results: Full Earnings Call Transcript

Acumen Pharmaceuticals Q1 EPS $(0.33) Beats $(0.36) Estimate

Acumen Pharmaceuticals shares are trading lower after the company reported a year-over-year decrease in Q4 EPS results.

Acumen Pharmaceuticals shares are trading lower after the company reported a year-over-year decrease in Q4 EPS results.

Acumen Pharmaceuticals, Inc. (ABOS) Q4 2025 Earnings Call Transcript

Acumen Pharmaceuticals Files Prospectus To Resell Up To 10,833,331 Shares From March 16, 2026 Private Placement

BTIG Reiterates Buy on Acumen Pharmaceuticals, Maintains $8 Price Target

Acumen Pharmaceuticals Inc (NASDAQ:ABOS) Reports Narrower-Than-Expected Q4 Loss, Provides Key Clinical Update

Acumen Pharmaceuticals Q4 EPS $(0.41) Beats $(0.43) Estimate

Acumen Pharmaceuticals FY2025 EPS Loss Of $2.00 Vs. Loss Of $1.71 YoY, Cash, Cash Equivalents And Marketable Securities Of $116.9M With Cash Runway Into Early 2027

Acumen Pharma Announces New Research Findings At International Conference On Alzheimer's And Parkinson's Diseases And Related Neurological Disorders

Acumen Pharmaceuticals shares are trading higher after the company announced a $35.75 million equity private placement at $3.30 per share.

Acumen Pharmaceuticals Announces Private Placement Of ~$35.75M At $3.30/Share

Acumen Pharmaceuticals to Showcase Advances in Alzheimer's Treatment at International Conference on Alzheimer’s and Parkinson’s Diseases 2026

Acumen Shares New Alzheimer's Drug Data At Global Brain Disease Conference

Assessing Acumen Pharmaceuticals (ABOS) Valuation After New Phase 2 ALTITUDE-AD Trial Developments